» Articles » PMID: 311815

The Tumor Dormant State. Quantitation of L5178Y Cells and Host Immune Responses During the Establishment and Course of Dormancy in Syngeneic DBA/2 Mice

Overview
Journal J Exp Med
Date 1979 Mar 1
PMID 311815
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Subcutaneous implantation of DBA/2-derived L5178Y cells into DBA/2 mice followed 10 d later by nodule excision protected 100% of mice from the rapid outgrowth of an intraperitoneal challenge of L5178Y cells given 7 d postexcision. Challenged mice remained clinically normal for 48--250 d before onset of an ultimately fatal tumor outgrowth. The numbers of L5178Y cells in the peritoneal cavity increased logarithmically for 4 d after challenge and then declined to low but detectable levels which persisted throughout the clinically normal period. Cells active in 18-h in vitro cytolytic assays against 51Cr-labeled L5178Y target cells were found in the peritoneal cavity. The effector cells were determined to be Thy1.2 positive. Their activity was tumor specific and reached peak levels 4 d after tumor challenge and then gradually declined to undectable levels during the following 70 d. Tumor emergence occurred most frequently during the period when CMC activity was no longer demonstrable in the remaining clinically normal mice. A transient peak of low level cytophilic antitumor antibody was detected about 30 d after tumor cell challenge. The temporal associations between the numbers of tumor cells and the levels of cell-mediated lysis against L5178Y cells indicate the importance of the cell-mediated cytolysis response in limiting initial tumor outgrowth and suggest its role as one of the factors responsible for long-term tumor suppression during tumor dormancy.

Citing Articles

Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.

Dong X, Xue H, Mo F, Lin Y, Lin D, Wong N Mol Cancer Res. 2022; 20(5):782-793.

PMID: 35082166 PMC: 9234014. DOI: 10.1158/1541-7786.MCR-21-1037.


The dormant cancer cell life cycle.

Phan T, Croucher P Nat Rev Cancer. 2020; 20(7):398-411.

PMID: 32488200 DOI: 10.1038/s41568-020-0263-0.


Tumor cell dormancy as an adaptive cell stress response mechanism.

Vera-Ramirez L, Hunter K F1000Res. 2017; 6:2134.

PMID: 29263786 PMC: 5730860. DOI: 10.12688/f1000research.12174.1.


Tuning cancer fate: the unremitting role of host immunity.

Cali B, Molon B, Viola A Open Biol. 2017; 7(4).

PMID: 28404796 PMC: 5413907. DOI: 10.1098/rsob.170006.


Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?.

Yeh A, Ramaswamy S Cancer Res. 2015; 75(23):5014-22.

PMID: 26354021 PMC: 4668214. DOI: 10.1158/0008-5472.CAN-15-1370.


References
1.
Fisher B, Fisher E . Experimental evidence in support of the dormant tumor cell. Science. 1959; 130(3380):918-9. DOI: 10.1126/science.130.3380.918. View

2.
Mendelsohn M . Chronic infusion of tritiated thymidine into mice with tumors. Science. 1962; 135(3499):213-5. DOI: 10.1126/science.135.3499.213. View

3.
Hadfield G . The dormant cancer cell. Br Med J. 1954; 2(4888):607-10. PMC: 2078920. DOI: 10.1136/bmj.2.4888.607. View

4.
Herberman R, Campbell Jr D, Oldham R, Bonnard G, Ting C, HOLDEN H . Immunogenicity of tumor antigens. Ann N Y Acad Sci. 1976; 276:26-44. DOI: 10.1111/j.1749-6632.1976.tb41634.x. View

5.
NORTH R, Kirstein D . T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. J Exp Med. 1977; 145(2):275-92. PMC: 2180603. DOI: 10.1084/jem.145.2.275. View